Genicular Artery Embolization (GAE)

Osteoarthritis (OA) of the knee is a degenerative joint condition in which the cartilage that cushions the ends of bones gradually wears away. Without this protective layer, bones begin to rub against one another, causing pain, stiffness, swelling, and reduced range of motion. Knee OA affects over 32 million Americans and is the leading cause of disability in older adults. The pain of OA is not driven solely by cartilage loss — a major contributor is synovitis, or inflammation of the joint lining (synovium). In OA, the synovium becomes infiltrated with abnormal new blood vessels (neovascularization) that feed inflammatory cells and pain-signaling nerves, amplifying discomfort well beyond what cartilage damage alone would explain.

Genicular artery embolization (GAE) is a minimally invasive procedure that targets the inflammatory blood supply feeding the painful synovium of an arthritic knee. By selectively blocking these abnormal neovessels with tiny embolic particles, GAE interrupts the inflammatory signaling that drives OA pain — without touching the joint itself. Unlike total knee replacement (TKR), GAE does not involve cutting, bone removal, implants, or general anesthesia. It is intended for patients with mild-to-moderate OA who wish to delay or avoid surgery, or for whom surgery carries too great a risk. It does not reverse cartilage damage, but it reliably reduces the pain that cartilage loss and synovitis generate.

Ideal GAE candidates are patients with knee pain from confirmed OA (Kellgren-Lawrence grade 1–3 on X-ray), who have had inadequate relief from conservative measures like physical therapy, NSAIDs, or corticosteroid/hyaluronic acid injections, and who wish to avoid or postpone knee replacement. GAE is also appropriate for patients who are not surgical candidates due to age, comorbidities, obesity, or anticoagulation requirements. Patients with severe OA (KL grade 4) or significant joint deformity may have less dramatic results, though still often benefit from pain reduction.

GAE is performed at our office-based lab under mild conscious sedation and local anesthesia. A microcatheter is advanced from the radial artery at the wrist to the genicular arteries supplying the knee’s synovial lining. Real-time fluoroscopy (X-ray) and digital subtraction angiography guide catheter positioning to identify hyperemic (abnormally vascular) synovial segments. Tiny embolic microspheres (100–300 microns) are then carefully injected to selectively block these vessels while sparing normal tissue. The procedure takes 45–90 minutes. Patients typically feel only pressure during needle placement and mild warmth during embolization — the procedure is well-tolerated. A light bandage is applied to the wrist; no sutures are needed.

Pain improvement typically begins within 2–4 weeks as inflammation subsides. Optimal benefit is usually reached at 4–8 weeks post-procedure. In published clinical trials, approximately 70–80% of patients report meaningful pain reduction at 6 months, with average Visual Analogue Scale (VAS) pain scores improving by 40–60%. Functional scores (KOOS, WOMAC) show parallel improvements. Some patients notice a dramatic response within days; others see gradual improvement over 2 months. The procedure can be repeated if needed.

Multiple published studies — including MRI follow-up — have confirmed that GAE does not damage joint cartilage, bone, or the normal genicular arterial blood supply. The embolic particles used are sized specifically to block only small neovascular channels, not the larger nutrient vessels that supply bone and cartilage. Post-procedure MRI studies show no evidence of avascular necrosis or accelerated cartilage loss. This favorable safety profile is one of GAE’s most important attributes — it does not preclude future knee replacement if ultimately needed.

Yes, bilateral GAE (treating both knees in one session) is feasible and is offered in appropriate cases. A single radial artery access point can be used to reach both sides. The decision to treat one or both knees simultaneously depends on the severity of symptoms in each knee, overall procedure time, and patient preference. Some patients prefer to treat the more symptomatic knee first and reassess before committing to bilateral treatment. Dr. Chahal will discuss the best approach at your consultation.

Corticosteroid injections offer rapid but typically short-lived relief (6–12 weeks on average) and repeated use can paradoxically accelerate cartilage degradation. PRP (platelet-rich plasma) has variable evidence and inconsistent results across trials. GAE acts through a distinct, longer-lasting mechanism — permanently reducing the inflammatory vascular supply — and clinical data show sustained benefit at 12 months and beyond, significantly outperforming the durability of injections. GAE and injections are not mutually exclusive; some patients have found that a corticosteroid injection helps bridge the gap while awaiting GAE’s onset of action.

Recovery is minimal. Most patients go home the same day and return to light activities within 1–2 days. There are no restrictions on weight-bearing — you can walk normally immediately after the procedure. Mild knee aching or puffiness for a few days post-procedure is common and manageable with over-the-counter anti-inflammatories. Patients are advised to avoid strenuous lower-body exercise for 1 week. A follow-up visit or telehealth check-in is scheduled at 4–6 weeks to assess early response.

GAE is an emerging procedure and coverage varies by payer. Medicare coverage is actively evolving; some Medicare Advantage and commercial plans cover GAE when documented medical necessity criteria are met (failed conservative therapy, imaging-confirmed OA, appropriate symptom burden). Our team aggressively pursues prior authorization and provides all required clinical documentation. Where coverage is denied, we work with patients to explore appeals and self-pay options. Contact our office for a personalized insurance verification before your consultation.